We Accelerate Discovery

You are here

Printer

Program Snapshot

Part of the Common Fund's High-Risk, High-Reward Research program, the New Innovator Award supports exceptionally creative, early-career investigators who propose innovative, high-impact projects with no preliminary data required.
 

Read more

Highlights

Mapping Body Language

Sandeep Datta, a 2010 New Innovator, developed new computational techniques that read complex patterns of behavior and body movements of mice and organizes them into units. The techniques eliminates the need for human observers (and their biases) and will lead to new insight into how the brain creates behavior and how that process is disrupted in disease. (View the video abstract Exit Disclaimer)

Read more


Extending Youth in Worms

Michael Petrascheck, a 2011 New Innovator, used an antidepressant drug to prolong life in roundworms by extending young adulthood. The drug fights against transcriptional drift and raises the possibility of using drugs to delay the onset of age-related disease.

Read more


New Model Shows Maternal Immune Cells Protect Against Severe Cytomegalovirus Disease

Sallie Permar, a 2012 New Innovator, developed a nonhuman primate model of congenital cytomegalovirus transmission (the leading infectious cause of childhood hearing loss and brain damage) and used the model to demonstrate the important role the maternal immune system plays in disease severity and fetal loss. The model opens the pathway for clinically-relevant congenital CMV vaccine development and research.

Read more

 

Application Information

•  Early stage investigator with no R01 or equivalent NIH grant
•  Within 10 years of doctoral degree or medical internship/residency
•  No preliminary data required
•  Awards up to $300K per year for up to 5 years
•  More information
 
Application Status
FY 2016 Closed

Announcements


Program Booklet  •  Abstracts  •  Photos Exit Disclaimer  •  Videocasts for Day 1Day 2, and Day 3


Keeping Worms Young

 

Michael Petrascheck, a 2011 New Innovator, was featured in The Guardian Exit Disclaimer and IFL Science! Exit Disclaimer for his use of an antidepressant drug to prolong life in roundworms by extending young adulthood. The drug fights against transcriptional drift and raises the possibility of using drugs to delay the onset of age-related disease.

Edward Boyden and Karl Deisseroth Receive 2016 Life Sciences Breakthrough Prize

 

Edward Boyden (2007 New Innovator, 2012 and 2013 Transformative Research, and 2013 Pioneer awardee) and Karl Deisseroth (2005 Pioneer and 2012 Transformative Research awardee) were awarded $3 million each for the 2016 Breakthrough Prize in Life SciencesExit Disclaimer


View Awardee Bios  •  Read Press Release


Child with Drug-Resistant TB Successfully Treated

 

Sanjay Jain, a 2009 awardee, successfully treated a 2-year old child with a highly virulent form of tuberculosis known as extensively drug-resistant (XDR) TB. The case is the first detailed account of a young child in the United States being diagnosed and treated for XDR TB. The case is published online in the November 16 edition of The Lancet Infectious Diseases. Read more at the Washington Post Exit Disclaimer.

Up to Top